PT - JOURNAL ARTICLE AU - Morobe, John Mwita AU - Pool, Brigitte AU - Marie, Lina AU - Didon, Dwayne AU - Lambisia, Arnold W. AU - Makori, Timothy AU - Mohammed, Khadija Said AU - de Laurent, Zaydah R. AU - Ndwiga, Leonard AU - Mburu, Maureen W. AU - Moraa, Edidah AU - Murunga, Nickson AU - Musyoki, Jennifer AU - Mwacharo, Jedida AU - Nyamako, Lydia AU - Riako, Debra AU - Ephnatus, Pariken AU - Gambo, Faith AU - Naimani, Josephine AU - Namulondo, Joyce AU - Tembo, Susan Zimba AU - Ogendi, Edwin AU - Balde, Thierno AU - Dratibi, Fred Athanasius AU - Ahmed, Yahaya Ali AU - Gumede, Nicksy AU - Achilla, Rachel A. AU - Borus, Peter K. AU - Wanjohi, Dorcas AU - Tessema, Sofonias K. AU - Mwangangi, Joseph AU - Bejon, Philip AU - Nokes, D. James AU - Ochola-Oyier, Lynette Isabella AU - Githinji, George AU - Biscornet, Leon AU - Agoti, Charles N. TI - Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020-2021 AID - 10.1101/2022.03.18.22272503 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.18.22272503 4099 - http://medrxiv.org/content/early/2022/03/29/2022.03.18.22272503.short 4100 - http://medrxiv.org/content/early/2022/03/29/2022.03.18.22272503.full AB - Seychelles, an archipelago of 155 islands in the Indian Ocean, had confirmed 24,788 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the 31st December 2021. The first SARS-CoV-2 cases in Seychelles were reported on the 14th of March 2020, but cases remained low until January 2021, when a surge of SARS-CoV-2 cases was observed on the islands. Here, we investigated the potential drivers of the surge by genomic analysis 1,056 SARS-CoV-2 positive samples collected in Seychelles between 14th March 2020 and 31st December 2021. The Seychelles genomes were classified into 32 Pango lineages, 1,042 of which fell within four variants of concern i.e., Alpha, Beta, Delta and Omicron. Sporadic cases of SARS-CoV-2 detected in Seychelles in 2020 were mainly of lineage B.1 (European origin) but this lineage was rapidly replaced by Beta variant starting January 2021, and which was also subsequently replaced by the Delta variant in May 2021 that dominated till November 2021 when Omicron cases were identified. Using ancestral state reconstruction approach, we estimated at least 78 independent SARS-CoV-2 introduction events into Seychelles during the study period. Majority of viral introductions into Seychelles occurred in 2021, despite substantial COVID-19 restrictions in place during this period. We conclude that the surge of SARS-CoV-2 cases in Seychelles in January 2021 was primarily due to the introduction of more transmissible SARS-CoV-2 variants into the islands.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis works was supported by the National Institute for Health Research (NIHR) (project references 17/63/82 and 16/136/33) using UK aid from the UK Government to support global health research, The UK Foreign, Commonwealth and Development Office and Wellcome Trust (grant# 220985/Z/20/Z) The views expressed in this publication are those of the author (s) and not necessarily those of NIHR or the Department of Health and Social Care, Foreign Commonwealth and Development Office. This work was also supported by the Seychelles Public Health Laboratory (Public Health Authority), Africa-CDC, WHO-Afro, WHO-Seychelles, ASLM, and WHO-Kenya offices.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The whole genome sequencing study protocol was reviewed and approved by the Scientific and Ethics Review Committee (SERU) at KEMRI, (SERU #4035). Individual patient consent requirement was waivered by the committee as the sequenced samples were part of the public health emergency response.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analysis script for this manuscript will be available from the Virus Epidemiology and Control, Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme data server, https://doi.org/10.7910/DVN/AYT2UA. https://doi.org/10.7910/DVN/AYT2UA